Antimicrobial stewardship and responsible information

Why the context matters

WHO’s antimicrobial-resistance overview explains that microorganisms can become resistant to the medicines used against them and that misuse and overuse contribute to the problem. Access to appropriate medicines and diagnostics is also part of the public-health challenge.

For a pharmaceutical website, this means that product availability and clinical suitability must remain separate questions. A broad catalogue should not encourage a reader to select an antibiotic based on familiarity, perceived strength or a commercial description.

Understanding AWaRe

The WHO AWaRe antibiotic book uses the Access, Watch and Reserve framework and provides clinical guidance for common infections. The WHO page also identifies later disease-specific guidelines and differences that are relevant while the book is being updated.

The practical consequence is to use the current WHO material together with applicable national guidance. A category or a paragraph taken from an older version should not be treated as an unchanging recommendation for every setting.

Classification is not a prescription

An antibiotic class or stewardship category helps organise professional information. It does not diagnose an infection, establish which organism is present, or determine the medicine appropriate for a particular patient. Those questions require the clinical context and qualified professional judgement.

A medicine’s presence on an essential-medicines list likewise does not approve a particular manufacturer’s product or establish a dose for a reader. Procurement need, product authorisation and patient treatment decisions are related but distinct.

Reading an antibiotic portfolio responsibly

Identify the exact active substance, any combination component, dosage form and strength. Then read the external clinical source in its own setting. A page concerning one formulation or route should not be generalised automatically to another presentation.

If the catalogue record does not contain an approved Luang Pharma label, do not fill that gap by copying treatment instructions from another company’s medicine. External links can make professional reading easier while keeping the source and the product-specific limits visible.

Questions for institutional discussions

A professional market or procurement discussion should begin with a defined requirement from the institution or competent clinical team. Product identity, approved presentation, intended channel, storage requirements and the lawful supply pathway are relevant parts of that conversation.

Forecasts and portfolio planning can then consider the stated need without replacing the clinical selection process. Comparisons should avoid unsupported claims that one listed candidate is “stronger”, “safer” or suitable for wider use than another.

A practical reading checklist

• Check the publication date and any linked update or correction.
• Confirm the infection, population and care setting addressed.
• Use the applicable national guidance and local professional context.
• Keep the manufacturer’s approval status separate from guideline recommendations.
• Refer patient-specific treatment questions to a qualified healthcare professional.

This resource does not provide antibiotic selection, dosing or treatment-duration instructions. It helps readers use serious public sources without confusing a development portfolio with prescribing guidance. The evidence guide gives a broader framework for evaluating linked medicine information.

Use AWaRe at the level it was designed for

WHO AWaRe groups antibiotics to support stewardship, monitoring and policy. It is not a substitute for an approved indication, local guideline, susceptibility information or an individual clinical decision. A category label should therefore not be converted into patient-specific treatment advice on a corporate portfolio page.

Stewardship information is most useful when it explains why antimicrobial choice, access and surveillance matter while directing prescribers to current local or national guidance. It should not be used to imply that an unregistered development product is recommended for a particular infection.

Responsible portfolio language

For development records, keep the generic identity and proposed presentation separate from therapeutic claims. Avoid language such as “first-line”, “preferred” or “recommended” unless the statement is accurately attributed to a current guideline and the scope is clear. Even then, the guideline does not approve the Luang Pharma record.

Commercial enquiries should identify the medicine, destination and regulatory context. Clinical questions about an individual patient belong with qualified healthcare professionals using current local guidance and authorised product information.